Crohn’s Disease (Regional Enteritis) (Gastrointestinal) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease – Drugs In Development, 2021, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 17, 41, 32, 3, 68, 31 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

4D Pharma Plc

9 Meters Biopharma Inc

AbbVie Inc

Abivax SA

Aclaris Therapeutics Inc

Active Biotech AB

Affilogic SAS

AIBIOS Co Ltd

Alfasigma SpA

Algernon Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Alvotech ehf

Amide Technologies Inc

Anterogen Co Ltd

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Artizan Biosciences Inc

Asdera LLC

Assembly Biosciences Inc

AstraZeneca Plc

Atlantic Healthcare Plc

Avexegen Therapeutics Inc

Avobis Bio LLC

Avotres Inc

Axim Biotechnologies Inc

Bio-Thera Solutions Ltd

BioLingus AG

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cellivery Therapeutics Inc

Celltrion Inc

Cellvation Inc

Celularity Inc

Cerecor Inc

ChemoCentryx Inc

Chong Kun Dang Pharmaceutical Corp

ChunLab Inc

Cloud Pharmaceuticals Inc

Curacle Co Ltd

CVasThera

Cytocom Inc

Cytodyn Inc

Dadang & BIO Co Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

Defensin Therapeutics ApS

Deka Biosciences Inc

Denali Therapeutics Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

EA Pharma Co Ltd

Eden Biologics Inc

Educell doo

Eisai Co Ltd

Eli Lilly and Co

Enterome Bioscience SA

Enzo Biochem Inc

Evergreen Therapeutics Inc

Exeliom Biosciences SAS

Ferring International Center SA

Finch Therapeutics Group Inc

FYB 202 GmbH & Co KG

Galactica Biotech Ltd

Galapagos NV

Genentech USA Inc

Genor BioPharma Co Ltd

Giiant Pharma Inc

GlaxoSmithKline Plc

Gossamer Bio Inc

Gusto Global LLC

HAV Vaccines Ltd

Hoth Therapeutics Inc

Iltoo Pharma

Immunic Inc

Inception Sciences Inc

InflammatoRx inc

Innovation Pharmaceuticals Inc

Innovative Pharmacological Research (IPHAR) Co Ltd

Innovent Biologics Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Inspyr Therapeutics Inc

Intract Pharma Ltd

Jiangsu Carephar Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

JiangSu Qyuns Therapeutics Co Ltd

Johnson & Johnson

Jyant Technologies Inc

Koutif Therapeutics LLC

Kyorin Pharmaceutical Co Ltd

Landos Biopharma Inc

Machavert Pharmaceuticals LLC

MAKScientific LLC

Mesoblast Ltd

Metacrine Inc

Metagen Therapeutics Inc

MetiMedi Pharmaceuticals Co Ltd

MGC Pharmaceuticals Ltd

Mitsubishi Tanabe Pharma Corp

Morphic Therapeutic Inc

MRM Health NV

Mycenax Biotech Inc

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Oncodesign SA

Orchard Therapeutics Plc

Origo Biopharma SL

PanTheryx Inc

Par'Immune SAS

Paradigm Biopharmaceuticals Ltd

PeLeMed Co Ltd

Pfizer Inc

Pharmapraxis

Polpharma Biologics SA

Praeventix LLC

Prometheus Biosciences Inc

Protagonist Therapeutics Inc

Puretech Health Plc

Qu Biologics Inc

Re-Pharm Ltd

Rebiotix Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Regentys Corp

Reistone Biopharma Co Ltd

Reponex Pharmaceuticals AS

Saje Pharma LLC

Samsung Bioepis Co Ltd

Saniona AB

Semorex Technologies Ltd

Seres Therapeutics Inc

Servatus Ltd

Siam Bioscience Co Ltd

SLA Pharma AG

Soligenix Inc

Steel Therapeutics Inc

Stempeutics Research Pvt Ltd

STERO Biotechs Ltd

Sublimity Therapeutics HoldCo Ltd

Suono Bio Inc

Surrozen Inc

Suzhou Connect Biopharmaceuticals Ltd

Suzhou Pharmavan Cancer Research Center Co Ltd

Synedgen Inc

Synlogic Inc

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Temisis Therapeutics

Tetherex Pharmaceuticals Corp

The Cell Factory BVBA

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tiziana Life Sciences Plc

TRACT Therapeutics Inc

Trio Medicines Ltd

UCB SA

Ventyx Biosciences Inc

VHsquared Ltd

VITAbolus Inc

Winston Pharmaceuticals Inc

XBiotech Inc

Xbrane Biopharma AB

Yom Chai

Table of Contents

Table of Contents

Introduction

Crohn's Disease (Regional Enteritis) - Overview

Crohn's Disease (Regional Enteritis) - Therapeutics Development

Crohn's Disease (Regional Enteritis) - Therapeutics Assessment

Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development

Crohn's Disease (Regional Enteritis) - Drug Profiles

Crohn's Disease (Regional Enteritis) - Dormant Projects

Crohn's Disease (Regional Enteritis) - Discontinued Products

Crohn's Disease (Regional Enteritis) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by 4D Pharma Plc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by 9 Meters Biopharma Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by AbbVie Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Abivax SA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Aclaris Therapeutics Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Active Biotech AB, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Affilogic SAS, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by AIBIOS Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Alfasigma SpA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Algernon Pharmaceuticals Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Alpha Cancer Technologies Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Alvotech ehf, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Amide Technologies Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Anterogen Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Arena Pharmaceuticals Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Artelo Biosciences Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Artizan Biosciences Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Asdera LLC, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Assembly Biosciences Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by AstraZeneca Plc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Atlantic Healthcare Plc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Avexegen Therapeutics Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Avobis Bio LLC, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Avotres Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Axim Biotechnologies Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Bio-Thera Solutions Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by BioLingus AG, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by BioXpress Therapeutics SA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Boehringer Ingelheim International GmbH, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Bristol-Myers Squibb Co, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cellivery Therapeutics Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Celltrion Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cellvation Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Celularity Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cerecor Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by ChemoCentryx Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by ChunLab Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cloud Pharmaceuticals Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Curacle Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by CVasThera, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cytocom Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Cytodyn Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Dadang & BIO Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by DBV Technologies SA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Defensin Therapeutics ApS, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Temisis Therapeutics, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Tetherex Pharmaceuticals Corp, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by The Cell Factory BVBA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Theravance Biopharma Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Thetis Pharmaceuticals LLC, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Tiziana Life Sciences Plc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by TRACT Therapeutics Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Trio Medicines Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by UCB SA, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Ventyx Biosciences Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by VHsquared Ltd, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by VITAbolus Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Winston Pharmaceuticals Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by XBiotech Inc, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Xbrane Biopharma AB, 2021

Crohn's Disease (Regional Enteritis) – Pipeline by Yom Chai, 2021

Crohn's Disease (Regional Enteritis) – Dormant Projects, 2021

Crohn's Disease (Regional Enteritis) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports